Levera

# Levera ## Overview - **Classification**: Antiepileptic Drug (AED), pyrrolidine derivative. - **Mechanism**: Exact mechanism unknown; binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release. ## Primary Indications 1. **Partial-Onset Seizures (POS)** - Monotherapy or adjunctive therapy in adults and children ≥ 1 month. 2. **Myoclonic Seizures (MS)** - Adjunctive therapy in adults and adolescents ≥ 12 years with Juvenile Myoclonic Epilepsy (JME). 3. **Primary Generalized Tonic-Clonic Seizures (PGTCS)** - Adjunctive therapy in adults and children ≥ 6 years with Idiopathic Generalized Epilepsy (IGE). ## Adult Dosing ### Standard Dosing **Partial-Onset Seizures (POS)** - **Dose**: Initial **500 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) or Intravenous (IV) infusion (over 15 min) - **Titration**: Increase by **500 mg BID** every 2 weeks to target **1500 mg BID** - **Maximum**: **1500 mg BID** (3000 mg/day) **Myoclonic Seizures (MS) / Primary Generalized Tonic-Clonic Seizures (PGTCS)** - **Dose**: Initial **500 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) or Intravenous (IV) infusion (over 15 min) - **Titration**: Increase by **500 mg BID** every 2 weeks to target **1500 mg BID** - **Maximum**: **1500 mg BID** (3000 mg/day) ### Dose Adjustments - **Renal Impairment**: Based on CrCl (mL/min) - **CrCl 50-79**: **500-1000 mg BID** - **CrCl 30-49**: **250-750 mg BID** - **CrCl <30 (Non-dialysis)**: **250-500 mg BID** - **ESRD (on Dialysis)**: **500-1000 mg daily** + **250-500 mg post-dialysis** - **Hepatic Impairment**: No specific adjustment for mild-moderate; monitor renal function in severe. - **Elderly Patients**: Start with lower doses; adjust based on renal function. ## Pediatric Dosing ### Neonates (0-28 days) **Partial-Onset Seizures (Adjunctive)** - **Dose**: Initial **7 mg/kg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) or Intravenous (IV) - **Titration**: May increase up to **21 mg/kg BID** - **Maximum**: **42 mg/kg/day** - **Special Notes**: Limited data, monitor closely for adverse effects. ### Infants (1-12 months) **Partial-Onset Seizures (Adjunctive)** - **Dose**: Initial **10 mg/kg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) or Intravenous (IV) - **Titration**: Increase by **10 mg/kg BID** every 2 weeks to target **30 mg/kg BID** - **Maximum**: **30 mg/kg BID** (60 mg/kg/day) ### Children (1-12 years) **Partial-Onset Seizures (Adjunctive)** - **Dose**: Initial **10 mg/kg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) or Intravenous (IV) - **Titration**: Increase by **10 mg/kg BID** every 2 weeks to target **30 mg/kg BID** - **Maximum**: **3000 mg/day** (or **1500 mg BID**) **Primary Generalized Tonic-Clonic / Myoclonic Seizures (Adjunctive, ≥ 6 years)** - **Dose**: Initial **10 mg/kg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) or Intravenous (IV) - **Titration**: Increase by **10 mg/kg BID** every 2 weeks to target **30 mg/kg BID** - **Maximum**: **3000 mg/day** (or **1500 mg BID**) ### Adolescents (13-18 years) **All Indications** - **Dose**: Approach adult dosing; start **500 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) or Intravenous (IV) - **Maximum**: **3000 mg/day** (or **1500 mg BID**) ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to levetiracetam or any pyrrolidone derivative. ### Common Adverse Effects - **Very Common (>10%)**: Somnolence, asthenia, dizziness, headache. - **Common (1-10%)**: Nausea, vomiting, diarrhea, abdominal pain, irritability, aggression, insomnia, anorexia. - **Serious but Rare**: Suicidal ideation, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), severe psychiatric/behavioral changes. ### Key Drug Interactions - **CNS Depressants (e.g., opioids, benzodiazepines)**: May enhance CNS depressant effects; monitor for sedation. - **Methotrexate**: Levetiracetam may decrease methotrexate clearance in rare cases; monitor methotrexate levels. - **Generally**: Levetiracetam has minimal drug interactions due to low protein binding and renal excretion. ## Monitoring & Follow-up - **Before Treatment**: Baseline renal function (CrCl calculation) is recommended. - **During Treatment**: Monitor for seizure control and adverse effects. - Renal function should be monitored, especially in patients with pre-existing impairment or elderly. - Monitor for behavioral changes, depression, or suicidal ideation. - **Clinical Signs**: Watch for new or worsening psychiatric symptoms, skin rash, or signs of infection (due to rare blood dyscrasias). ## Clinical Pearls - 💡 **No routine TDM**: Therapeutic drug monitoring is generally not required due to predictable pharmacokinetics. - 💡 **Taper slowly**: Abrupt discontinuation can increase seizure frequency; taper over 2-4 weeks. - 💡 **Versatile**: Available in PO, IV, and extended-release formulations, offering flexibility. - 💡 **Behavioral effects**: Inform patients/caregivers about potential behavioral and psychiatric side effects, especially in children. - 💡 **Pregnancy**: Considered safer than many other AEDs, but still requires careful risk/benefit assessment. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.